Systemic neglect of sex-specific kidney research perpetuates inequitable healthcare outcomes globally
Original framing: “[Series] Advances in understanding the impact of sex on kidney health and disease” — The Lancet
The exclusion of women from clinical research dates back to the 1977 FDA policy banning their participation in trials, a decision rooted in fears of fetal harm that ignored women’s historical exclusion from medical authority. The Tuskegee Syphilis Study and other unethical experiments further entrenched mistrust in medical institutions among marginalized groups, shaping contemporary disparities in kidney disease outcomes. The Lancet’s series echoes 19th-century debates on 'hysteria' and 'female weakness,' where sex differences were medicalized to justify exclusion rather than inclusion.
The Lancet’s series inadvertently reveals a crisis of epistemic violence in nephrology, where the neglect of sex-specific differences is not an oversight but a structural feature of a system that prioritizes male bodies, corporate profits, and colonial legacies over equitable care.
Indigenous knowledge systems—from Māori *rongoā* to Ayurvedic *dosha* theory—offer holistic frameworks that could transform kidney disease treatment, yet these are dismissed as 'unscientific' while Western medicine’s reductionist paradigms fail patients. The historical exclusion of women and marginalized groups from clinical research, coupled with the pharmaceutical industry’s profit-driven erasure of sex differences, creates a feedback loop of harm that disproportionately affects Black women, transgender individuals, and low-income communities. A systemic solution requires decolonizing research, mandating inclusive trial designs, and centering marginalized voices in both policy and practice—transforming kidney health from a site of inequity into a model of reparative medicine. The trickster’s laughter reminds us that the absurdity of this neglect is not inevitable; it is a choice, and one we can unmake.